211 related articles for article (PubMed ID: 36934836)
21. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
Xu B; Chen Y; Peng M; Zheng JH; Zuo C
Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
[TBL] [Abstract][Full Text] [Related]
22. Tumor microenvironment crosstalk between tumors and the nervous system in pancreatic cancer: Molecular mechanisms and clinical perspectives.
Xu W; Liu J; Zhang J; Lu J; Guo J
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189032. PubMed ID: 38036106
[TBL] [Abstract][Full Text] [Related]
23. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.
Tang D; Wang D; Yuan Z; Xue X; Zhang Y; An Y; Chen J; Tu M; Lu Z; Wei J; Jiang K; Miao Y
Int J Cancer; 2013 Mar; 132(5):993-1003. PubMed ID: 22777597
[TBL] [Abstract][Full Text] [Related]
24. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.
Chen SJ; Lian GD; Li JJ; Zhang QB; Zeng LJ; Yang KG; Huang CM; Li YQ; Chen YT; Huang KH
Cancer Med; 2018 Nov; 7(11):5679-5690. PubMed ID: 30311406
[TBL] [Abstract][Full Text] [Related]
25. Functional and Clinical Proteomic Exploration of Pancreatic Cancer.
Huang P; Gao W; Fu C; Tian R
Mol Cell Proteomics; 2023 Jul; 22(7):100575. PubMed ID: 37209817
[TBL] [Abstract][Full Text] [Related]
26. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
27. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts.
Novák Š; Kolář M; Szabó A; Vernerová Z; Lacina L; Strnad H; Šáchová J; Hradilová M; Havránek J; Španko M; Čoma M; Urban L; Kaňuchová M; Melegová N; Gürlich R; Dvořák J; Smetana K; Gál P; Szabo P
Cancer Genomics Proteomics; 2021; 18(3):221-243. PubMed ID: 33893076
[TBL] [Abstract][Full Text] [Related]
28. Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines.
Girish BP; Dariya B; Mannarapu M; Nagaraju GP; Raju GSR
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1155-1162. PubMed ID: 34147639
[TBL] [Abstract][Full Text] [Related]
29. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
30. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.
Andersen HB; Ialchina R; Pedersen SF; Czaplinska D
Cancer Metastasis Rev; 2021 Dec; 40(4):1093-1114. PubMed ID: 34855109
[TBL] [Abstract][Full Text] [Related]
31. Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment.
Wu TC; Liao CY; Lu WC; Chang CR; Tsai FY; Jiang SS; Chen TH; Lin KM; Chen LT; Chang WW
J Exp Clin Cancer Res; 2022 Apr; 41(1):137. PubMed ID: 35410237
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
34. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
[TBL] [Abstract][Full Text] [Related]
35. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
[TBL] [Abstract][Full Text] [Related]
36. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
37. Crosstalk between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in the Tumor Microenvironment Mediated by Exosomal MicroRNAs.
Chu X; Yang Y; Tian X
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076911
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
40. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.
Lu T; Prakash J
Int J Nanomedicine; 2021; 16():6313-6328. PubMed ID: 34552327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
